Pettiti Gianluca sold $2.9M of TMO
Pettiti Gianluca (President & COO) sold 4,133 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at $701.42 ($2.90M total) across 2 trades on 2026-11-13 under a Rule 10b5-1 trading plan.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific provides products and services to customers in pharmaceutical and biotechnology companies, hospitals, clinical diagnostic laboratories, universities, research institutions, government agencies, and environmental, industrial and research settings. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Its offerings include research reagents and instruments, analytical and diagnostic products, laboratory supplies, and outsourced drug development, clinical research, clinical trials and commercial manufacturing services. Thermo Fisher sells through a direct sales force, customer-service professionals, e-commerce and third-party distributors, and offers products and services under brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. Its business includes both self-manufactured and sourced products, as well as services for pharmaceutical and biotech companies. Thermo Fisher is headquartered in Waltham, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Pettiti Gianluca (President & COO) sold 4,133 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at $701.42 ($2.90M total) across 2 trades on 2026-11-13 under a Rule 10b5-1 trading plan.
Cape EMS Bhd, a Malaysia-based electronics manufacturing company, has finalized a contract with Thermo Fisher Scientific for life sciences projects. The agreement, effective August 20, 2026, spans three years with possible extensions. Cape EMS's subsidiary, iConn Technologies, will support research, development, and production across the US, Europe, and Asia. The deal aligns with Cape EMS's Intelligent Manufacturing Network strategy.
mDETECT and Thermo Fisher Scientific launched a research assay for cancer detection via methylation profiling of circulating tumor DNA (ctDNA) in blood samples. The Ion AmpliSeq HD Lung Cancer cfDNA Methylation Assay combines mDETECT's methylation analysis with Thermo Fisher's Ion AmpliSeq HD technology. Biodesix will evaluate the assay for lung cancer diagnostics. The assay is for research use only, not yet for diagnostics.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning TMO (THERMO FISHER SCIENTIFIC INC.). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent TMO coverage spans technology, corporate actions and insider activity.
In the last 30 days, TMO insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($4.9M). The most active reporter was Pettiti Gianluca, President & COO, with 2 filings. 67% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider selling by a top executive is a modest negative signal, but the 10b5-1 structure reduces interpretive weight.
The agreement adds a new customer in Southeast Asia, potentially boosting TMO's life‑sciences revenue.
Potential modest upside as the assay may drive research spend on Thermo Fisher's NGS platforms.
The launch adds a lower‑cost instrument to Thermo Fisher's portfolio, potentially expanding market share in metal analysis labs.
The new product is a modest price‑sensitive offering for labs; unlikely to drive immediate price movement.
AlphAI scores every news story that mentions TMO with an AI model for sentiment and relevance, and aggregates insider trades from THERMO FISHER SCIENTIFIC INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pettiti Gianluca (President & COO) sold 4,133 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at $701.42 ($2.90M total) across 2 trades on 2026-11-13 under a Rule 10b5-1 trading plan.
Cape EMS Bhd, a Malaysia-based electronics manufacturing company, has finalized a contract with Thermo Fisher Scientific for life sciences projects. The agreement, effective August 20, 2026, spans three years with possible extensions. Cape EMS's subsidiary, iConn Technologies, will support research, development, and production across the US, Europe, and Asia. The deal aligns with Cape EMS's Intelligent Manufacturing Network strategy.
mDETECT and Thermo Fisher Scientific launched a research assay for cancer detection via methylation profiling of circulating tumor DNA (ctDNA) in blood samples. The Ion AmpliSeq HD Lung Cancer cfDNA Methylation Assay combines mDETECT's methylation analysis with Thermo Fisher's Ion AmpliSeq HD technology. Biodesix will evaluate the assay for lung cancer diagnostics. The assay is for research use only, not yet for diagnostics.
Thermo Fisher Scientific launched the ARL Spark Companion OES Metal Analyzer, a benchtop system for routine metal composition analysis. The company claims it offers 25-second analysis times and is designed for in-house quality control. The analyzer is targeted at labs needing routine QC without high-end spectrometer capabilities, with applications in foundries, metal processing, and recycling. It complements Thermo Fisher's existing floor-standing systems.
Thermo Fisher Scientific launched Thermo Scientific AmpSure Universal SYBR Green and Probe Master Mixes for qPCR, offering value-priced, reliable performance. The mixes are compatible with various instruments and workflows, supporting gene expression analysis, genotyping, and microbe detection. The company aims to help labs balance performance and budget without changing existing workflows. Thermo Fisher Scientific reported annual revenue over $45 billion.
Thermo Fisher Scientific (TMO) authorized a $5B share repurchase program, replacing the prior $1B remaining. The company has shown recent earnings growth and outperforming units.
Thermo Fisher Scientific announced a $0.47 per share quarterly dividend, matching its prior payment. The forward yield is 0.28%. The dividend is payable on January 15, with a record date of December 15 and ex-dividend date of December 15.
Thermo Fisher Scientific's board authorized a $5 billion share buyback with no expiration, replacing a prior $1 billion authorization. The company reported $45 billion in annual revenue. (TMO)
Thermo Fisher Scientific (TMO) declared a quarterly cash dividend of $0.47 per share, payable January 15, 2027, to shareholders of record December 15, 2026. The company reported annual revenue exceeding $45 billion.
Thermo Fisher Scientific launched the Orbitrap Isora and Orbitrap Isora Pro Mass Spectrometers, its first Orbitrap instruments with a dedicated isotope ratio analysis mode. The instruments, paired with the Vanquish Duo UHPLC System and new Isotope Discoverer Software, aim to make molecular-level isotope ratio analysis more accessible to researchers in various fields. According to the company, the workflow simplifies analysis and provides detailed insights into a sample's origin and history.